Ahn-Gook Pharmaceutical Co., Ltd.

KOSDAQ:A001540 Stock Report

Market Cap: ₩116.6b

Ahn-Gook Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ahn-Gook Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth22.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article Mar 27

Some May Be Optimistic About Ahn-Gook Pharmaceutical's (KOSDAQ:001540) Earnings

The market for Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) shares didn't move much after it posted weak...
Analysis Article Dec 02

Earnings Working Against Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) Share Price

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 14x, you may consider...
Analysis Article Mar 28

Shareholders Shouldn’t Be Too Comfortable With Ahn-Gook Pharmaceutical's (KOSDAQ:001540) Strong Earnings

Even though Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) posted strong earnings recently, the stock hasn't...
Analysis Article Aug 26

Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

We didn't see Ahn-Gook Pharmaceutical Co., Ltd.'s ( KOSDAQ:001540 ) stock surge when it reported robust earnings...
Analysis Article Aug 13

Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now

With a price-to-earnings (or "P/E") ratio of 13.7x Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) may be sending...
Analysis Article Apr 02

Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Dividend paying stocks like Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) tend to be popular with investors, and...
Analysis Article Mar 07

Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year

We believe investing is smart because history shows that stock markets go higher in the long term. But if you choose...
Analysis Article Feb 14

Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Jan 19

Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

A look at the shareholders of Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) can tell us which group is most...
Analysis Article Dec 24

Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Analysis Article Dec 10

A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)

Does the December share price for Ahn-Gook Pharmaceutical Co., Ltd. ( KOSDAQ:001540 ) reflect what it's really worth...
Analysis Article Nov 18

Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend

Could Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) be an attractive dividend share to own for the long haul...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ahn-Gook Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A001540 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026330,05016,26841,46050,794N/A
12/31/2025306,8747,48137,08745,683N/A
9/30/2025300,9589,87937,22243,275N/A
6/30/2025290,7756,10329,70137,997N/A
3/31/2025281,12812,6328,49820,714N/A
12/31/2024271,11616,845-71,3684,914N/A
9/30/2024264,63614,281-69,9557,359N/A
6/30/2024252,48015,349-84,230-10,239N/A
3/31/2024244,2236,406-85,562-16,249N/A
12/31/2023233,6761,290-7,511-1,328N/A
9/30/2023226,1864,581-10,356-4,583N/A
6/30/2023224,2197,8013,7929,035N/A
3/31/2023213,4148,2982,9057,430N/A
12/31/2022205,3896,875-1,8781,788N/A
9/30/2022195,7409,4712,3315,745N/A
6/30/2022182,7607,005-6923,063N/A
3/31/2022175,1634,077-1,8743,319N/A
12/31/2021163,5343,939-3,5911,472N/A
9/30/2021149,1371,391-26,212-698N/A
6/30/2021143,734242-29,439-3,761N/A
3/31/2021141,126-2,505-20,8923,766N/A
12/31/2020143,364-1,315-13,28411,190N/A
9/30/2020156,318-1,0036,18410,332N/A
6/30/2020160,05921521,59824,970N/A
3/31/2020158,8703,33914,30617,727N/A
12/31/2019155,8522,536N/A22,078N/A
9/30/2019167,3927,416N/A21,312N/A
6/30/2019173,0648,524N/A1,395N/A
3/31/2019179,16612,862N/A1,748N/A
12/31/2018185,74613,220N/A-1,201N/A
9/30/2018177,6637,111N/A11,493N/A
6/30/2018177,6018,641N/A17,725N/A
3/31/2018179,5568,209N/A16,010N/A
12/31/2017183,6008,159N/A17,464N/A
9/30/2017182,0329,839N/A3,862N/A
6/30/2017179,0485,884N/A9,188N/A
3/31/2017176,1782,700N/A13,122N/A
12/31/2016174,0021,715N/A12,622N/A
9/30/2016183,923-185N/A21,903N/A
6/30/2016188,1943,025N/A20,365N/A
3/31/2016195,8717,926N/A26,472N/A
12/31/2015197,7369,364N/A19,106N/A
9/30/2015185,5694,360N/A10,633N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A001540's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A001540's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A001540's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A001540's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A001540's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A001540's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 19:26
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ahn-Gook Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Min-young LeeKorea Investment & Securities Co., Ltd.